한빛사 논문
Hye Ryun Kim1*‡ , Su-Myeong Park2*, Sang-Uk Seo2,3, Inkyung Jung1, Hong In Yoon1, Dmitry I. Gabrilovich4, Byoung Chul Cho1,5‡, Seung-Yong Seong2,3‡, Sang-Jun Ha6‡ , and Je-In Youn 2,3,6‡§
1 Yonsei University College of Medicine Seoul, Korea
2 Seoul National University College of Medicine Seoul, Korea
3 Seoul National University College of Medicine Hongcheon, Korea
4 Wistar Institute Philadelphia, Pennsylvania
5 JEUK Co., Ltd. Gumi City, Korea and
6 Yonsei University Seoul, Korea
*These authors contributed equally to this work.
‡Joint principal investigators who contributed equally to this study.
§Corresponding author
Abstract
Immune checkpoint inhibitors (ICIs) have emerged as a promising treatment modality for patients with non-small cell lung cancer (NSCLC). However, ICI monotherapy has a relatively low response rate (approximately 20-50% in patients with NSCLC) (1), and consequently it is important to develop predictive biomarkers of response to inform clinical decisions regarding ICI use. Although PD-L1 expression on tumor cells is currently used as a predictive determinant for anti-PD-1 therapy responses, the accuracy of this test is relatively poor. Therefore, better predictive biomarkers for anti-PD-1 therapy in patients with NSCLC are needed.
논문정보
관련 링크
연구자 ID
관련분야 연구자보기
관련분야 논문보기